In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant ...

June is the Myasthenia Gravis Month set aside to raise awareness about the breakdown between muscles and the nervous system. A 14-year-old survivor ASAMALA CHAPITA*, who refused to be broken by pain ...

Candid Therapeutics, Inc. ("Candid"), a clinical-stage biotechnology company redefining the treatment of autoimmune and ...

Telitacicept is a dual-targeting agent that attaches to and blocks the effects of 2 key signaling proteins, B-lymphocyte ...